Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.19
(1.33%)
SEK 0.19
(1.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -42.22 Million SEK | -21.23% |
| 2022 | -38.72 Million SEK | -0.1% |
| 2021 | -38.69 Million SEK | -108.12% |
| 2020 | -18.59 Million SEK | 6.03% |
| 2019 | -19.73 Million SEK | -84.63% |
| 2018 | -10.71 Million SEK | -21.7% |
| 2017 | -8.91 Million SEK | -25.36% |
| 2016 | -7.02 Million SEK | -8.19% |
| 2015 | -12.33 Million SEK | -15.87% |
| 2014 | -5.6 Million SEK | -19.31% |
| 2013 | -4.69 Million SEK | -40.94% |
| 2012 | -3.33 Million SEK | -511.38% |
| 2011 | -545 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.01 Million SEK | 35.29% |
| 2024 Q2 | -9.61 Million SEK | -4.49% |
| 2023 Q2 | -8.03 Million SEK | 44.8% |
| 2023 Q3 | -7.23 Million SEK | 9.92% |
| 2023 FY | - SEK | -21.23% |
| 2023 Q4 | -11.16 Million SEK | -54.18% |
| 2023 Q1 | -14.55 Million SEK | -33.99% |
| 2022 FY | - SEK | -0.1% |
| 2022 Q1 | -9.81 Million SEK | 11.68% |
| 2022 Q4 | -10.86 Million SEK | -26.87% |
| 2022 Q3 | -8.56 Million SEK | 9.73% |
| 2022 Q2 | -9.48 Million SEK | 3.32% |
| 2021 Q3 | -10.05 Million SEK | 12.93% |
| 2021 Q1 | -5.98 Million SEK | -31.52% |
| 2021 Q4 | -11.11 Million SEK | -10.54% |
| 2021 Q2 | -11.54 Million SEK | -92.96% |
| 2021 FY | - SEK | -108.12% |
| 2020 FY | - SEK | 6.03% |
| 2020 Q1 | -4.97 Million SEK | 14.34% |
| 2020 Q2 | -4.68 Million SEK | 5.83% |
| 2020 Q3 | -4.38 Million SEK | 6.53% |
| 2020 Q4 | -4.54 Million SEK | -3.86% |
| 2019 Q2 | -4.44 Million SEK | 1.42% |
| 2019 Q4 | -5.8 Million SEK | -15.79% |
| 2019 Q3 | -5.01 Million SEK | -12.79% |
| 2019 FY | - SEK | -84.63% |
| 2019 Q1 | -4.51 Million SEK | -40.6% |
| 2018 Q1 | -2.36 Million SEK | 15.12% |
| 2018 Q3 | -2.14 Million SEK | 28.3% |
| 2018 Q4 | -3.2 Million SEK | -49.39% |
| 2018 FY | - SEK | -21.7% |
| 2018 Q2 | -2.99 Million SEK | -26.79% |
| 2017 Q3 | -1.84 Million SEK | 23.18% |
| 2017 Q4 | -2.78 Million SEK | -50.81% |
| 2017 FY | - SEK | -25.36% |
| 2017 Q1 | -1.87 Million SEK | -13.96% |
| 2017 Q2 | -2.4 Million SEK | -27.96% |
| 2016 Q1 | -2.14 Million SEK | -126.23% |
| 2016 FY | - SEK | -8.19% |
| 2016 Q4 | -1.64 Million SEK | -37.45% |
| 2016 Q3 | -1.19 Million SEK | 40.99% |
| 2016 Q2 | -2.03 Million SEK | 5.27% |
| 2015 Q3 | -1.25 Million SEK | 32.66% |
| 2015 Q2 | -1.86 Million SEK | 8.57% |
| 2015 Q1 | -2.04 Million SEK | -2.92% |
| 2015 Q4 | 8.17 Million SEK | 750.0% |
| 2015 FY | - SEK | -15.87% |
| 2014 FY | - SEK | -19.31% |
| 2014 Q4 | -1.98 Million SEK | -148.44% |
| 2014 Q3 | -799 Thousand SEK | 53.6% |
| 2014 Q2 | -1.72 Million SEK | -56.97% |
| 2014 Q1 | -1.09 Million SEK | 53.75% |
| 2013 Q1 | -1.24 Million SEK | -11.98% |
| 2013 Q3 | -992 Thousand SEK | -1014.61% |
| 2013 Q4 | -2.37 Million SEK | -139.11% |
| 2013 FY | - SEK | -40.94% |
| 2013 Q2 | -89 Thousand SEK | 92.84% |
| 2012 FY | - SEK | -511.38% |
| 2012 Q4 | -1.11 Million SEK | -60.64% |
| 2012 Q2 | -756 Thousand SEK | 2.45% |
| 2012 Q3 | -691 Thousand SEK | 8.6% |
| 2012 Q1 | -775 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 88.52% |
| Camurus AB (publ) | 562.54 Million SEK | 107.506% |
| Mendus AB (publ) | -97.84 Million SEK | 56.846% |
| Lipum AB (publ) | -37.11 Million SEK | -13.753% |
| NextCell Pharma AB | -40.98 Million SEK | -3.023% |
| Simris Alg AB (publ) | -22.36 Million SEK | -88.812% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -147.148% |
| Active Biotech AB (publ) | -43.88 Million SEK | 3.789% |
| Amniotics AB (publ) | -27.14 Million SEK | -55.561% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -196.997% |
| BioArctic AB (publ) | 275.38 Million SEK | 115.333% |
| Cantargia AB (publ) | -284.31 Million SEK | 85.149% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -115.66% |
| CombiGene AB (publ) | -35.33 Million SEK | -19.493% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 70.022% |
| Genovis AB (publ.) | 64.57 Million SEK | 165.391% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 63.254% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -14.045% |
| Intervacc AB (publ) | -68.98 Million SEK | 38.788% |
| Kancera AB (publ) | -61.88 Million SEK | 31.775% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -57.652% |
| LIDDS AB (publ) | -39.67 Million SEK | -6.438% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -248.843% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 234.454% |
| OncoZenge AB (publ) | 7.26 Million SEK | 681.118% |
| Saniona AB (publ) | -69.69 Million SEK | 39.416% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 86.7% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 85.029% |
| Xintela AB (publ) | -53.47 Million SEK | 21.034% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 75.135% |
| Ziccum AB (publ) | -20.34 Million SEK | -107.571% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2111300.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 82.23% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1930.0% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -214.377% |
| Corline Biomedical AB | -1.69 Million SEK | -2396.984% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 75.639% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 22.957% |
| Aptahem AB (publ) | -10 Million SEK | -321.851% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 465.607% |
| Fluicell AB (publ) | -25.91 Million SEK | -62.939% |
| Biovica International AB (publ) | -119.5 Million SEK | 64.668% |
| AcouSort AB (publ) | -16.7 Million SEK | -152.793% |
| Abliva AB (publ) | -93.6 Million SEK | 54.893% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 86.768% |
| 2cureX AB (publ) | -35.13 Million SEK | -20.173% |
| I-Tech AB | 30.34 Million SEK | 239.146% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 94.091% |
| Cyxone AB (publ) | -20.41 Million SEK | -106.838% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 58.787% |
| Biosergen AB | 228 Thousand SEK | 18619.298% |
| Nanologica AB (publ) | -62.11 Million SEK | 32.027% |
| SynAct Pharma AB | -222.7 Million SEK | 81.04% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 3.732% |
| BioInvent International AB (publ) | -312.7 Million SEK | 86.497% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 13746.485% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 100635.727% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 81.77% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -379.139% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 61.105% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -268.158% |